Commentary: Little evidence of effective prenatal treatment against congenital toxoplasmosis--the implications for testing in pregnancy.
Eskild
A
A
Section of Epidemiology, National Institute of Public Health, PO Box 4404 Nydalen, 0403 Oslo, Norway.
Magnus
P
P
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000981:Antiprotozoal Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control*; D018942:Macrolides; D011181:Postnatal Care; D011247:Pregnancy; D015597:Pregnancy Complications, Parasitic / Q000175:diagnosis / Q000188:drug therapy; D011295:Prenatal Care; D011296:Prenatal Diagnosis; D014125:Toxoplasmosis, Congenital / Q000175:diagnosis / Q000188:drug therapy / Q000635:transmission*
D000900:Anti-Bacterial Agents; D000981:Antiprotozoal Agents; D018942:Macrolides